As we prepare to move ahead with our plans to take Gufic to the next level of successthe worldwide crisis of Covid-19 has hit almost every country every industry and almostevery business including ours. The performance of the financial year 2019-20 has beenchallenging yet satisfying for us since the year saw many approvals for us in terms ofvarious regulatory approvals for our plant. These approvals stands as a testimony of ourcommitment to quality adherence to compliance manufacturing excellence strong research& development team dedication to provide affordable medicines to public and trust ofall the stakeholders.
With the investment on the manufacturing front Gufic group is now all set to enhanceour manufacturing capacity of the lyophilized products to around 50 million Vials bySeptember 2020.This will help us to explore the business opportunities in variouscountries with the product pipelines being built by us in the immediate and long termfuture.
The Domestic business for us has been progressing well especially in the Critical caresegment where the company features in the Top 5 companies and continues to consolidate itspresence every year.
The Company's drive in the domestic business has started paying off as it has enteredthe Top 100 companies ranking (February 2020) by reaching a position of 92 with a CAGR39.4%.
With a well spread portfolio in Critical care Infertility and mass specialty productswe now cover almost 90 % of the tertiary care hospitals and more than 1 lakh doctors andover 2 lakh retail counters. The focus of every division is to increase the number ofprescribers and prescriptions and eventually build high value brands. We now have morethan 12 brands with more than Rs. 5 crores sales and the strategy is to nurture thesebrands further to earn leadership position in the respective segments. We have severalbrands(12) ranked among the top 5 brands in the relevant competing segments-which gives usconfidence to build brands Apart from our plans to consolidate the strong segments likeCriticare care and Infertility Gufic has already chalked out plans to create separateteams to cater to Orthopedics and Gynecologists in the metro cities.
Looking at the Pandemic scenario and its impact of the therapy areas we havere-strategized some of our therapy areas in the portfolio and have started buildingCovid-centric products like some anti-infectives Sepsis products and Peptites to managethe critically ill patients in the tertiary care hospitals.
In the year 2020 Gufic is all set to enter the high growth Dermatology segment withevidence based Aesthetic Dermatology products with technical collaborations with companiesbased in USA and France. It's a pleasure to announce that Gufic is one of the 5 companiesin the World which is fully equipped to manufacture high quality Botulinum Toxin. Ourstate-of the art facility at Navsari can manufacture Botulinum toxin successfullycomplying to the stringent Global standards of quality.
We will have a separate highly skilled team to promote these products to high endCosmetologists and Plastic surgeons in India. The team would be functional by the month ofDecember 2020.
We are also in the process of seeking approval for new drug delivery systems for theBotulinum Neurotoxin for first time users which do not prefer the injectable route.
In the financial year 2019-20 the Company has achieved total revenue of Rs. 36456.63lakhs over Rs. 35494.18 lakhs in the previous year and net profit after tax of Rs. 2285.67lakhs over Rs. 2194.07 lakhs in the previous year respectively. The EBITDA growth of thecompany has increased by 2.47 % in comparison with the previous year. We have grownconsistently both in terms of revenue as well as profits. The growth of the company wasmainly attributed to the performance of Criticalcare businessthe CMO Buisness and theinternational partnerships that we nurtured for the past few years.
During the year under review your Company launched around 8 new products and madecontinuous efforts for improvising the existing products. R& D has around 30 activeprojects in the pipeline. 3 clinical trials have been initiated in India in the field ofanti-virals resistant bacterial infections and dermatology
Your company's Active Pharmaceutical Ingredient (API) business has seen good growth.Your company also plans to increase the pipeline of API product offering by at least 6more products in FY 2020-21 which will drive the API business further and also utilizeincreased capacities. Your Company's annual API manufacturing capacity has been increasedby 36 tons which will contribute in revenue growth in the future.
Your Company is also in talks with several international companies for in-licensinginnovative concepts in various therapy areas such as Dermatology nutritional infertilityand anti-infectives.
We remain focused on improving quality across all aspects of our operations withinitiatives for continuous improvement reducing manual interventions through digitizationand automated equipment's. We intend to continue this journey and meet the highestregulatory standards for our manufacturing facilities and new product development.
Further your Company is awaiting sanction of Scheme of Amalgamation of GuficLifesciences Private Limited (GLPL) with the Company by the requisite regulatoryauthorities. The manufacturing unit of GLPL is EU-GMP certified and this Scheme onbecoming effective would provide larger asset base to the Company and enable furthergrowth and development of the Company especially in terms of Exports.
Our thanks to the management team and all our employees for coming together to deliverbetter results and many thanks to you for your support.
With best regards
For Gufic Biosciences Limited
Jayesh P. Choksi
Chairman & Managing Director